pharma news today glp-1 obesity drugs today Dozens of new are coming: these are the ones to watch India's fast-growing weight-loss drug market

Market growth is fueled by the increased rates of type 2 diabetes and obesity over the world, increased awareness of cardiovascular effects linked to GLP-1 therapies, increased uptake of new dual and triple agonist preparations, and positive regulatory endorsements of weight loss phenotypes

10.1089/ars.2018.7569 6 Anna MartinaB.AlessandroS.EleonoraV.StefaniaS.LaviniaP.EmanueleG.et al (2023)

The treatment has substantial clinical trial support for various musculoskeletal conditions

Although Pol- has relatively low affinity for these analogues (100), their incorporation causes premature chain termination during mtDNA replication, leading to mtDNA depletion, reduced expression of -encoded OXPHOS subunits, and ultimately impaired ETC function and ATP production (101103)

This strategy has been applied to dulaglutide, where two GLP-1 molecules are fused to the Fc fragment of IgG4, increasing the half-life while reducing the renal elimination due to the increased molecular weight